1. Scrip
  2. >>New Products

Iovance Lucks Out With Amtagvi

 
• By Elizabeth Cairns

The long-delayed accelerated approval of the melanoma T-cell therapy comes a week early, and with a generous label.    

Iovance

After a long and pitfall-strewn campaign, Iovance Biotherapeutics, Inc. has finally scored US accelerated approval of its T-cell therapy lifileucel for certain melanoma patients. The company’s share price rose by 33% to $12.14 after the close on 16 February on the NASDAQ, presumably on investors’ sheer relief.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.

Quotables: Pharma Leaders On The Month’s Hot Topics

 
• By Anabel Costa-Ferreira

The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.

In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis

 
• By Sushmita Panda

JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.